Trending Topics in Gastroenterology | GastroAGI

Semaglutide for MASLD: AASLD Practice Guidance November 2025

As of my knowledge cutoff in October 2023, I cannot provide specific details about the AASLD Practice Guidance from November 2025 regarding semaglutide for MASLD (metabolic dysfunction-associated steatotic liver disease). However, based on the provided context and existing knowledge, I can offer a projected understanding of how semaglutide might fit into MASLD treatment according to evolving clinical guidance. ### Overview of Semaglutide in MASLD Management (Based on Context) 1. **FDA Approval for MASH (2025)**: - Semaglutide (Wegovy®) received accelerated FDA approval in August 2025 for treating metabolic dysfunction-associated steatohepatitis (MASH) with stage F2–F3 fibrosis based on the ESSENCE Phase 3 trial results. 2. **Efficacy in MASH**: - The ESSENCE trial demonstrated significant histologic improvements: - MASH resolution in 62.9% of patients. - Fibrosis reduction in 36.8% of patients compared to placebo. 3. **Noninvasive Diagnosis and Monitoring**: - The AASLD recommends noninvasive tests (NITs) such as VCTE (FibroScan), MRE, or ELF for fibrosis assessment, discouraging routine liver biopsies. - Recommended NIT ranges for identifying treatment candidates: - VCTE: 8–15 kPa. - MRE: 3.1–4.4 kPa. - ELF: 9.2–10.5. 4. **Exclusion of Cirrhosis**: - Patients with evidence of cirrhosis (e.g., VCTE > 20 kPa, MRE > 5 kPa, or ELF > 11.3) are not candidates for semaglutide as a sole treatment for MASH. 5. **Safety and Adverse Effects**: - Semaglutide has a favorable hepatic safety profile, with no liver enzyme-related discontinuations in the ESSENCE trial. - Common mild side effects include nausea, diarrhea, constipation, and vomiting. - Rare but serious risks include acute kidney injury, gallbladder disease, pancreatitis, thyroid C-cell tumors, and retinopathy progression. - Lean mass loss (~13% in trials) requires attention to exercise and protein intake. 6. **Lifestyle Modifications as Core Therapy**: - Dietary changes, weight management, and physical activity remain foundational in MASH therapy, even with semaglutide use. 7. **Cardiovascular and Renal Benefits**: - Semaglutide reduces major adverse cardiovascular events (MACE) in obese or diabetic patients and likely provides similar benefits for MASH patients. - The FLOW trial (2025) showed reduced risk of kidney failure and cardiovascular death in T2DM patients with chronic kidney disease. 8. **Indicators of Response and Non-Response**: - Positive response indicators: ALT reduction (>17 U/L or >20%), CAP > 30%, VCTE ≥ 30%, MRE ≥ 20%, or ELF > 0.5 from baseline. - Non-response: Worsening ALT or NIT values may suggest treatment futility, requiring reassessment or discontinuation. ### Projected AASLD Guidance (November 2025) While specific details of the November 2025 AASLD Practice Guidance are unavailable, it is reasonable to expect the following recommendations based on the context: 1. **Eligibility Criteria**: - Patients with MASLD (specifically MASH) and moderate to advanced fibrosis (F2–F3) may be considered for semaglutide therapy. - Noninvasive tests (NITs) should guide patient selection, avoiding liver biopsies unless absolutely necessary. 2. **Exclusion of Cirrhosis**: - Patients with cirrhosis should not receive semaglutide for MASH treatment alone, as its efficacy in advanced liver disease remains unproven. 3. **Safety and Monitoring**: - Routine liver function tests are not required unless clinically indicated. - Patients should be monitored for potential adverse effects, including gastrointestinal symptoms, lean mass loss, and rare complications like pancreatitis or retinopathy. 4. **Lifestyle Interventions**: - Lifestyle changes, including diet, exercise, and weight loss, remain the cornerstone of MASLD management and should accompany semaglutide therapy. 5. **Combination Therapy**: - The guidance may advise caution regarding concurrent use of semaglutide with other investigational agents like resmetirom, as formal studies on combination therapy are lacking. 6. **Long-Term Outcome Verification**: - The AASLD may emphasize the need for long-term outcome data from the ESSENCE trial (expected by 2028 or later) to confirm the durability of semaglutide's benefits in MASH. ### Conclusion Semaglutide represents a promising therapeutic option for MASH with F2–F3 fibrosis, supported by strong clinical trial evidence (ESSENCE). However, its use should align with AASLD recommendations, focusing on appropriate patient selection, safety monitoring, and integration with lifestyle modifications. For definitive details on the November 2025 AASLD Practice Guidance, consulting the official document or updates beyond October 2023 is essential.

M-ACCEL trial

The M-ACCEL trial is a phase IIa study that evaluated the investigational oral drug HU6 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This trial aimed to assess the drug's efficacy in reducing liver fat and its impact on body composition over a 26-week treatment period. HU6 was tested in three daily doses: 150 mg, 300 mg, and 450 mg, alongside a placebo group for comparison. The trial demonstrated that HU6 significantly reduced liver fat in patients with MASH. Patients receiving HU6 experienced reductions in liver fat content of 29.4%, 31.2%, and 27% for the 150 mg, 300 mg, and 450 mg doses, respectively, compared to only 6.7% in the placebo group—a statistically significant difference (P=0.005). More than half of the patients on HU6 achieved at least a 30% reduction in liver fat, far exceeding the 22% response rate in the placebo group. Importantly, these reductions occurred without loss of skeletal muscle mass, which is critical for managing weight-related liver diseases. Additionally, HU6 impacted body composition, with the 450-mg dose leading to significant fat loss (–2.4 kg) compared to placebo (–0.9 kg). Muscle mass remained stable across all HU6 groups. HU6 functions as a controlled metabolic accelerator, increasing mitochondrial energy usage, and offers a promising oral treatment option for MASH with mild side effects and good safety profiles.

The ELMWOOD- Phase II trial

The ELMWOOD Phase II trial is a clinical study evaluating the efficacy and safety of elafibranor (brand name Iqirvo) for the treatment of primary sclerosing cholangitis (PSC). PSC is a rare, chronic liver disease that causes inflammation, scarring, and narrowing of the bile ducts, which can eventually lead to liver failure. Currently, there are no approved treatments for PSC, making this an area of significant unmet medical need. ### Key Findings from the ELMWOOD Phase II Trial: 1. **Study Design**: - The trial included an open-label extension phase, where patients who initially received a placebo were switched to elafibranor at a 120 mg daily dose. Other participants either continued on their original treatment dose or had their dose increased. 2. **Efficacy Results**: - **Alkaline Phosphatase (ALP)**: - ALP is a key liver enzyme and biomarker linked to disease activity in PSC. - Patients who switched from placebo to elafibranor (120 mg daily) experienced rapid and sustained reductions in ALP levels: - A 36% reduction in ALP at week 4. - A 40% reduction in ALP at week 28. - Patients who had been on the 120 mg dose from the start of the trial achieved even greater reductions: - A 46% reduction in ALP at week 28. - Patients whose dose was increased from 80 mg to 120 mg showed a 35.6% reduction in ALP, indicating continued improvement with higher dosing. - **Other Liver Enzymes**: - Elafibranor also improved levels of other liver enzymes, including ALT, AST, GGT, and bilirubin, across all treatment groups. - **Pruritus (Itching)**: - Itching, one of the most debilitating symptoms of PSC, improved in all treatment cohorts. - **Fibrosis Assessments**: - Noninvasive measures of liver fibrosis showed stabilization or modest improvement, suggesting potential long-term benefits for liver health. 3. **Safety Profile**: - The safety findings were generally acceptable: - 52% of patients reported treatment-emergent side effects, most of which were mild. Common side effects included COVID-19, nausea, itching, and weight gain. - Serious adverse events occurred in 5% of participants, but none were attributed to elafibranor. - The safety data supports the continued development of elafibranor for PSC. 4. **Significance**: - The interim results indicate that elafibranor is a promising therapeutic candidate for PSC. It has demonstrated meaningful improvements in liver markers, symptoms like pruritus, and potentially slowed disease progression. This is particularly important given the lack of approved treatments for this rare and serious liver disease. ### Conclusion: The ELMWOOD Phase II trial highlights elafibranor's potential to address the significant unmet medical need in PSC. Its ability to improve liver enzyme levels, alleviate symptoms, and potentially impact long-term liver health makes it a promising therapy for further clinical development.

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist

**GLP-1 Receptor Agonist Overview** A GLP-1 receptor agonist is a type of medication that mimics the action of the hormone glucagon-like peptide-1 (GLP-1). GLP-1 is a naturally occurring hormone that helps regulate blood sugar levels, appetite, and digestion. These drugs are widely used in the treatment of type 2 diabetes and obesity. They work by increasing insulin secretion, slowing gastric emptying, and reducing appetite, which leads to weight loss and improved blood sugar control. **Why an Oral GLP-1 Agonist is Needed** Traditional GLP-1 receptor agonists, like semaglutide, are administered via injection, which can be inconvenient or undesirable for some patients. An oral GLP-1 agonist, such as Orforglipron, offers a convenient, non-invasive alternative, potentially improving patient adherence and accessibility for long-term obesity and metabolic disorder management. **What is Orforglipron?** Orforglipron is a novel, nonpeptide, small-molecule GLP-1 receptor agonist specifically designed for oral administration. It represents a significant advancement in obesity treatment by providing an effective, convenient alternative to injectable GLP-1 therapies. Beyond weight loss, Orforglipron also offers cardiometabolic benefits, such as improved blood pressure, cholesterol, and triglyceride levels. **Study Summary (100 Words)** A 72-week phase 3 trial evaluated Orforglipron, an oral GLP-1 receptor agonist, in 3,127 adults with obesity (without diabetes). Participants received 6 mg, 12 mg, or 36 mg daily doses or placebo, alongside lifestyle modifications. Orforglipron demonstrated dose-dependent weight loss (up to −11.2% with 36 mg vs. −2.1% placebo), with 54.6% of the 36 mg group losing ≥10% of body weight. Cardiometabolic markers, including waist circumference, blood pressure, and lipids, improved significantly. Adverse effects, mainly gastrointestinal, were mild to moderate. Orforglipron’s efficacy and safety profile matched injectable GLP-1 therapies, making it a promising oral alternative for long-term obesity management.

Tobacco and MASLD

Tobacco use, both active and passive, significantly influences the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). Active smoking increases MASLD risk through mechanisms such as oxidative stress, inflammation, and metabolic disruption. Tobacco-induced oxidative stress damages liver cells (hepatocytes), promotes insulin resistance, and facilitates fat deposition in the liver, which are hallmark features of MASLD. Smoking also elevates systemic inflammatory markers like C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6), exacerbating hepatic inflammation and fibrosis. Additionally, smoking disrupts the gut–liver axis by altering gut microbiota, increasing intestinal permeability, and allowing endotoxins to enter the liver, further driving inflammation. The risk of MASLD is dose-dependent, with smokers who consume ≥20 pack-years of tobacco experiencing a 32% higher risk, highlighting the cumulative effect of tobacco exposure. Passive smoking, or secondhand smoke exposure, also contributes to MASLD, increasing risk by 13%. This underscores the harmful effects of indirect tobacco exposure, which impacts liver function even in non-smokers. Metabolic factors amplify the impact of smoking on MASLD. Individuals with obesity (BMI ≥24), hypertension, or high triglycerides face significantly higher risk due to the synergistic effects of smoking and metabolic dysfunction. Smoking impairs insulin signaling and lipid metabolism, worsening metabolic and hepatic health. Older adults and those with cardiometabolic conditions are particularly vulnerable. Importantly, smoking cessation has a protective effect. Quitting for more than 10 years reduces MASLD risk close to that of non-smokers, though damage persists for those who quit less than 10 years ago. Public health initiatives targeting smoking cessation and secondhand smoke regulation are crucial for MASLD prevention.

GLP-1 Receptor Agonists and Gastrointestinal Adverse Events

GLP-1 receptor agonists (GLP-1RAs) are medications commonly used to treat type 2 diabetes, obesity, and metabolic liver diseases. A meta-analysis of 55 randomized trials involving over 106,000 participants examined their gastrointestinal safety. The study found that GLP-1RAs are linked to a 46% higher risk of cholelithiasis (gallstones), which equals about 2 extra cases per 1000 people treated. Additionally, they were associated with a twofold increased risk of gastroesophageal reflux disease (GERD), leading to 4 extra cases per 1000 patients. However, no significant increase was observed in other gastrointestinal risks like pancreatitis, cholangitis, or intestinal obstruction. The risks of gallstones and GERD were more pronounced in patients with obesity, liver conditions like MASLD/MASH, those using GLP-1RAs for weight loss, or taking higher doses. These effects may result from rapid weight loss and reduced gallbladder motility (for gallstones) or delayed gastric emptying (for GERD). Despite these risks, GLP-1RAs are considered safe overall, as severe gastrointestinal complications were not significantly elevated. Clinicians should monitor gallbladder and reflux symptoms in patients on GLP-1RAs, especially those on weight-loss formulations or higher doses. The benefits of these drugs often outweigh their modest risks, making them a valuable therapeutic option.

Autoantibodies and outcome of MASLD

Autoantibodies, specifically ANA (antinuclear antibodies) and ASMA (anti-smooth muscle antibodies), are immune system proteins that mistakenly target the body’s own tissues. These autoantibodies were studied in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) to understand their impact on disease progression and outcomes. The research found that autoantibodies are relatively common in MASLD, with 17% of patients testing positive for ANA, 25% for ASMA, and 8% positive for both. The presence of these autoantibodies significantly worsens the prognosis of MASLD. Patients who tested positive for ANA or ASMA had a nearly fourfold higher risk of liver decompensation and over twofold higher risk of death compared to those without autoantibodies. Autoantibody positivity independently predicted progression to advanced liver disease, even after accounting for other risk factors like obesity and diabetes. The study suggests that these autoantibodies act as markers of systemic or liver inflammation rather than directly causing damage. Increased inflammation linked to autoantibodies reflects heightened immune activation, which contributes to disease severity. MASLD patients with autoantibodies often present with advanced fibrosis (F3–F4) and are at higher risk for complications like compensated advanced chronic liver disease (cACLD), hepatocellular carcinoma (HCC), and death. Screening for ANA and ASMA can help identify high-risk patients for closer monitoring and tailored treatment.

T2DM, GLP-1 Receptor Agonists and Liver Protection

GLP-1 receptor agonists (GLP-1RAs) have emerged as a promising therapeutic option for type 2 diabetes mellitus (T2DM) due to their multifaceted benefits, including significant liver protection. Here is a detailed explanation of their role in liver health and protection: ### 1. **Significant Hepatocellular Carcinoma (HCC) Risk Reduction** GLP-1RAs have been shown to markedly lower the risk of hepatocellular carcinoma (HCC), a primary form of liver cancer. Compared to other diabetes medications such as insulin and sulfonylureas: - **GLP-1RAs vs. Insulin**: GLP-1RAs reduced HCC risk with a hazard ratio (HR) of 0.20, indicating an 80% lower risk compared to insulin use. - **GLP-1RAs vs. Sulfonylureas**: The risk reduction was also significant (HR 0.78), showcasing their superior protective effects. ### 2. **Broad Liver-Protective Effects** GLP-1RAs consistently demonstrated hepatic protection across six different comparator drug classes. These agents reduce the risk of hepatic decompensation, a severe consequence of liver disease, suggesting their broad and reliable liver-protective properties. ### 3. **Independent of Weight Loss** The liver benefits of GLP-1RAs are not solely dependent on weight loss, which is a common effect of these drugs. Both obese and non-obese patients experienced reduced HCC risk, highlighting the direct impact of GLP-1RAs on liver health, independent of their metabolic effects. ### 4. **Enhanced Benefits in the Absence of Insulin** Patients who were not using insulin showed stronger liver-protective effects with GLP-1RA therapy. This observation suggests that insulin may exert negative influences on liver health, which are not entirely mitigated by GLP-1RAs when used in combination. ### 5. **Protection Across All Stages of Liver Disease** GLP-1RAs have demonstrated efficacy in reducing HCC risk across various stages of liver disease, including: - **MASLD/MASH** (Metabolic Associated Steatotic Liver Disease/Metabolic Associated Steatohepatitis) - **Fibrosis** - **Cirrhosis** This suggests that GLP-1RAs are effective in preventing liver disease progression and associated complications. ### 6. **Preventive Potential in Patients Without Liver Disease** Even in patients without pre-existing liver conditions (MASLD, MASH, or cirrhosis), GLP-1RA therapy reduced the risk of HCC. This underscores their preventive potential, making them valuable for liver health in broader patient populations. ### 7. **Substance Use Influence** GLP-1RAs significantly lowered HCC risk in patients who did not use alcohol or tobacco. However, in patients who did use these substances, the liver-protective effects were smaller and did not reach statistical significance. This suggests that lifestyle factors may influence the efficacy of GLP-1RAs in liver protection. ### 8. **Combination Therapy Advantage** When GLP-1RAs were combined with other diabetes medications such as SGLT2 inhibitors or thiazolidinediones, the benefits were enhanced: - **HCC Risk Reduction**: Combination therapy provided greater protection against liver cancer. - **Hepatic Decompensation Risk Reduction**: The combined use amplified the liver-protective effects beyond those seen with GLP-1RA monotherapy. ### 9. **Caution with Insulin Combination** The combination of GLP-1RAs and insulin was less effective in reducing HCC risk compared to GLP-1RA monotherapy. This suggests that insulin may have carcinogenic mechanisms that are not fully counteracted by GLP-1RAs. ### 10. **Real-World Evidence and Safety** In a large U.S. cohort study involving over 1.8 million patients, GLP-1RAs demonstrated robust liver-protective associations without increasing serious adverse events. This real-world evidence supports their safety and efficacy in managing liver-related risks in T2DM patients. ### Summary GLP-1 receptor agonists offer substantial liver protection in patients with type 2 diabetes, reducing the risk of HCC and hepatic decompensation across various stages of liver disease. Their benefits extend beyond weight loss and are enhanced when combined with other medications like SGLT2 inhibitors or thiazolidinediones. However, caution is warranted when using GLP-1RAs in combination with insulin, as the protective effects may be diminished. GLP-1RAs also show preventive potential in patients without liver disease and maintain their efficacy in real-world settings, making them a valuable option for liver health management in T2DM.

2D-SWE in MASLD

Two-dimensional shear wave elastography (2D-SWE) is a non-invasive imaging technique used to measure liver stiffness, which helps assess the severity of liver fibrosis. Liver fibrosis occurs when scar tissue builds up in the liver, often due to conditions like metabolic dysfunction-associated steatotic liver disease (MASLD), a liver condition linked to obesity and metabolic issues. Early detection of fibrosis is critical, as advanced stages (like cirrhosis) increase the risk of complications such as liver failure or cancer. 2D-SWE works by sending ultrasound waves into the liver and measuring how quickly shear waves travel through the tissue. Stiffer liver tissue, often caused by fibrosis, results in faster wave propagation. This method is gaining attention because it provides accurate, reproducible results and is relatively easy to perform. In MASLD, 2D-SWE is particularly useful because it overcomes some limitations of older techniques like vibration-controlled transient elastography (VCTE), which can be less accurate in obese patients. A recent meta-analysis has established standardized cutoff values for 2D-SWE to improve its diagnostic accuracy for different stages of fibrosis. By integrating 2D-SWE into clinical practice, healthcare providers can better identify high-risk MASLD patients, enabling earlier interventions and improved management of liver health.

A new generation of non-invasive tests of liver fibrosis in MASLD

The new generation of non-invasive tests (NITs) for liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) are advanced diagnostic tools developed using machine learning and multitargeting approaches. These tests aim to improve the accuracy and reliability of diagnosing advanced fibrosis (F3–F4) in MASLD patients, addressing the limitations of conventional NITs. ### 1. **New Generation Markers Developed:** Three new multitargeted NITs were introduced in the study: - **FIB-9**: A model based solely on commonly available blood parameters. - **FIB-11**: A model incorporating additional specialized fibrosis markers. - **FIB-12**: The most advanced model, combining blood-based markers with liver stiffness measurement (LSM). These models were developed using **ADORE machine learning software**, which optimized predictions across multiple fibrosis stages simultaneously, surpassing the accuracy of traditional single-target statistical methods. --- ### 2. **Performance of New Generation Markers:** - **FIB-12**: - Achieved the highest diagnostic accuracy at **83.3%** in binary classification (AUROC 0.912). - Outperformed conventional NITs like FIB-4, FibroTest, FibroMeter, ELF, and Elasto-FibroMeter (EFM), all of which had accuracies below 80%. - Demonstrated superior accuracy over traditional tests in both binary and ordinal segmentation analyses, with over **90% accuracy in 41.5% of patients**. - Showed robust performance across different patient subgroups, including those with diabetes, older age, or varying disease complexity. - Was particularly effective for diagnosing fibrosis stages F2–F3, which are critical therapeutic targets for emerging MASLD treatments like resmetirom. - **FIB-9**: - A practical and cost-effective option, relying on routine laboratory parameters. - Achieved accuracy comparable to commercial fibrosis panels (AUROC 0.863). - Available as a **free online calculator**, making it highly accessible for primary care and mass screening. - **FIB-11**: - Showed slightly reduced precision in older or diabetic populations but still demonstrated strong overall performance. - Can complement FIB-12 in quaternary segmentation strategies to enhance diagnostic reliability. --- ### 3. **Comparison with Conventional Markers:** Traditional NITs, such as FIB-4, FibroTest, FibroMeter, ELF, and LSM, have been widely used for assessing liver fibrosis. However, these tests often fall short in terms of diagnostic accuracy, particularly in MASLD, due to the metabolic complexity of the disease. For example: - FIB-4 and FibroTest typically have accuracy rates below 80%. - The ELF test demonstrated an AUROC of 0.865, which was significantly lower than FIB-12's AUROC of 0.912. The new generation models (FIB-9, FIB-11, and FIB-12) represent a significant advancement, providing higher accuracy, fewer indeterminate results, and enhanced clinical utility. --- ### 4. **Clinical Implications of New Generation Markers:** The development of these AI-based NITs has several key clinical implications: - **Improved Diagnostic Accuracy**: - The new models, particularly FIB-12, offer better precision for identifying advanced fibrosis, addressing the diagnostic gaps of traditional tests. - FIB-12 showed strong diagnostic performance for F2–F3 fibrosis, the therapeutic target range for MASLD treatments. - **Reduced Indeterminate Results**: - FIB-12 achieved the lowest indeterminate rate (16.4%) and the highest accuracy (up to 92%) in determinate cases when patients were classified into ruled-in, ruled-out, and indeterminate groups. - **Cost-Effectiveness and Accessibility**: - FIB-9, as a free online tool, enables healthcare providers to estimate fibrosis stage using basic lab results, making it ideal for mass screening and use in primary care settings. - **Enhanced Screening and Staging Efficiency**: - The multitarget design of the new models allows for more reliable staging of fibrosis, which is critical for clinical decision-making and treatment planning. - The **Fibs+ algorithm**, which integrates FIB-9, FIB-11, and FIB-12, outperformed existing clinical guidelines from the AGA, AASLD, and EASL for fibrosis detection. - **Broader Applicability Across Patient Populations**: - FIB-12 maintained high accuracy across different subgroups, including older patients and those with diabetes, ensuring its utility in diverse clinical settings. --- ### 5. **Conclusion:** The new generation of non-invasive tests—FIB-9, FIB-11, and FIB-12—represents a major advancement in the assessment of liver fibrosis in MASLD. These AI-enhanced models deliver significantly higher accuracy, fewer indeterminate results, and broader clinical utility compared to conventional NITs. Among these, **FIB-12** is the most accurate and reliable tool for advanced fibrosis diagnosis, while **FIB-9** offers a practical, cost-free option for mass screening. These tests are poised to improve clinical workflows, enhance early detection, and facilitate better management of MASLD.